PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “HEART VALVE PROSTHESIS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources
PubMed1980

Triple heart valve prosthesis and pregnancy.

An unusual case of a successful pregnancy in a patient with aortic, mitral, and tricuspid heart valve prostheses is presented and pertinent management problems are discussed. Although anticoagulation offers protection to the mother from thromboembolic episodes, it carries a high risk for maternal morbidity and fetal wastage.

Adult↗
PubMed2003

Midterm experience with the Sorin Bicarbon heart valve prosthesis for rheumatic disease.

BACKGROUND: In this study, we present a single center experience with Bicarbon bileaflet valve in 307 patients with rheumatic heart disease. METHODS: Between August 1998 and September 2000, 307 patients underwent heart valve replacement using the Bicarbon bileaflet valve (Sorin Biomedica, Saluggia, Italy) with an average age of 47.19+/-13.21 years (range 14 to 80 years), consisting of 147 males and 160 females at Alkan Hospital, Cardiovascular Surgery Department. Aortic valve replacement (AVR) was performed in 77 patients, mitral valve replacement (MVR) in 156 patients and double valve replacement (DVR) in 74 patients. RESULTS: The early mortality rate was 3.3% (10/307) and there was no late mortality. The actuarial survival rate, including hospital mortality, was 96.74+/-1.01% for the whole group, 96.5+/-1.5% for the MVR group, 97.4+/-1.8% for the AVR group and 97.3+/-1.9% for the DVR group at 35 months. One patient had obstructive valve thrombosis with MVR. The 35 months actuarial freedom from valve thrombosis was 99.58+/-0.4% for the whole group. Four patients were reoperated and the 35 months actuarial freedom from reoperation was 98.53+/-0.7% for the whole group, 98.65+/-0.9% for the MVR group, 96.73+/-02% for the DVR group and 100% for the AVR group. No instances of perivalvular leak, hemolysis, endocarditis or embolism were observed during the entire follow-up period. Mean follow-up duration was 16.5+/-7.9 months (ranged 4 to 35 months). CONCLUSION: We have presented our mid-term results with the Sorin Bicarbon bileaflet valve in patients with rheumatic heart disease, which provided good clinical performance combined with meticulous patient care and advanced surgical techniques.

Adolescent↗
PubMed1976

[Iron deficiency following implantation of a heart valve prosthesis].

In 44 patients with single or multiple valvular protheses of the heart, the problem of secondary iron deficiency due to mechanical hemolysis was investigated. In 17 cases, elevated serum transferrin values were noted, compared to elevated serum iron levels in only 6 cases. Therefore, treatment should be based on the more reliable transferrin values. Severity and duration of mechanical hemolysis did not seem to be correlated with the occurrence or the degree of iron deficiency.

Adult↗
PubMed1975

Cardiovascular management of pregnant women with a heart valve prosthesis.

This study of 14 pregnancies in 11 patients with a Starr-Edwards valve prosthesis (nine mitral, two aortic) shows that cardiac functional capacity deteriorated to class III (New York Heart Association criteria) in only 1 woman. The deterioration occurred during the third trimester and the patient's condition improved with medical therapy. Careful medical control diminished the incidence of heart failure in these patients. Six of nine pregnant women with a mitral valve prosthesis were treated continuously with coumarin and three discontinued the therapy gradually before the third trimester of pregnancy. In five pregnant women (three with an aortic valve prosthesis, two with a mitral valve prosthesis) no anticoagulant agents were used. No embolic episodes or severe hemorrhagic complications were seen. One newborn whose mother received coumarin during the first trimester had bilateral hand polydactylia. There were no maternal deaths. One neonate died after fetal stress necessitating the only cesarean section. These results suggest that women with an artificial heart valve tolerate pregnancy well and that anticoagulant therapy is not mandatory in pregnant women with an aortic valve prosthesis, or in the few women with a mitral valve prosthesis not already receiving coumarin at the onset of pregnancy.

Adult↗